Skip to main content
CMPX
NASDAQ Life Sciences

Compass Q3 Loss Widens to $27.2M as Tovecimig Manufacturing Spend Jumps; $163M Cash Runs Into 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.76
Mkt Cap
$136.651M
52W Low
$0.671
52W High
$6.88
52W Position info
13% above low
Off High info
89% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CMPX is trading near its 52-week low of $0.671 (13% above the low).

Summary

Compass posted a $27.2 million Q3 2026 net loss versus $14.3 million a year ago, with R&D up 72% on tovecimig manufacturing costs. Cash of $163 million is expected to fund operations into 2028, and no ATM shares were sold in the first nine months of 2026.


Key Events · Earnings and Guidance · CMPX

  • Q3 Loss Nearly Doubles

    Net loss was $27.2 million for the three months ended September 30, 2026, versus $14.3 million in the prior-year quarter; nine-month loss reached $70.6 million versus $50.8 million.

  • Tovecimig Manufacturing Drives R&D

    R&D rose 72% to $22.0 million in Q3, primarily from $8.6 million of tovecimig manufacturing costs; nine-month R&D was $55.0 million, up $12.7 million.

  • Cash Runway Into 2028

    Cash, cash equivalents and marketable securities totaled $163 million at September 30, 2026, which management expects to fund operating expenses and capital expenditures into 2028.

  • No ATM Shares Sold

    Under the December 2025 sales agreement with Leerink and Cantor Fitzgerald, the company sold no shares of common stock in the first nine months of 2026.


Analysis · CMPX · Life Sciences

The quarter's loss nearly doubled to $27.2 million from $14.3 million a year ago, driven mostly by $8.6 million of tovecimig manufacturing costs as the company builds drug supply ahead of a BLA it has not yet been cleared to file. That spending is a bet on approval, and the FDA's September recommendation for a new survival trial is the risk hanging over it. Against that, $163 million of cash and securities funds operations into 2028, so there is no near-term financing need and no ATM usage in the first nine months of 2026 — the dilution risk is deferred, not eliminated.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CMPX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.7M. The 52-week trading range was $0.67 to $6.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CMPX - Latest Insights

CMPX
Nov 09, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.760
Real-time Price: $0.7678 info
Change: +$0.0078 (+1%) info
Market Cap: $139.352M info
CMPX
Sep 22, 2026, 8:30 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.58
Real-time Price: $0.7678 info
Change: -$0.8122 (-51%) info
Market Cap: $139.352M info
CMPX
Aug 06, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $0.7678 info
Change: -$1.16 (-60%) info
Market Cap: $139.352M info
CMPX
Aug 06, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.94
Real-time Price: $0.7678 info
Change: -$1.17 (-60%) info
Market Cap: $139.352M info
CMPX
Aug 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $0.7678 info
Change: -$1.16 (-60%) info
Market Cap: $139.352M info